Innoviva Research and Development Expenses 2010-2024 | INVA
Innoviva research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Innoviva Annual Research and Development Expenses
(Millions of US $) |
| 2024 |
$14 |
| 2023 |
$34 |
| 2022 |
$41 |
| 2021 |
$1 |
| 2020 |
$2 |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$1 |
| 2016 |
$1 |
| 2015 |
$3 |
| 2014 |
$7 |
| 2013 |
$9 |
| 2012 |
$8 |
| 2011 |
$104 |
| 2010 |
$75 |
| 2009 |
$78 |
Innoviva Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-12-31 |
$4 |
| 2024-09-30 |
$4 |
| 2024-06-30 |
$3 |
| 2024-03-31 |
$4 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$15 |
| 2023-03-31 |
$13 |
| 2022-12-31 |
$10 |
| 2022-09-30 |
$12 |
| 2022-06-30 |
$14 |
| 2022-03-31 |
$6 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$0 |
| 2021-06-30 |
$0 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$0 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$1 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$1 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$2 |
| 2014-03-31 |
$3 |
| 2013-12-31 |
$-22 |
| 2013-09-30 |
$2 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
$26 |
| 2012-12-31 |
$28 |
| 2012-09-30 |
$27 |
| 2012-06-30 |
$30 |
| 2012-03-31 |
$33 |
| 2011-12-31 |
$32 |
| 2011-09-30 |
$28 |
| 2011-06-30 |
$23 |
| 2011-03-31 |
$20 |
| 2010-12-31 |
$17 |
| 2010-09-30 |
$19 |
| 2010-06-30 |
$19 |
| 2010-03-31 |
$20 |
| 2009-12-31 |
$18 |
| 2009-09-30 |
$20 |
| 2009-06-30 |
$20 |
| 2009-03-31 |
$20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.132B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
